Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

Unknown 20 enrolled Peking University People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

Zanubrutinib is a novel BTK inhibitor with proven activity in patients with various B-cell lymphomas addicted to the B-cell receptor signaling pathway.

Timeline

Start: 2021-09
Primary completion: 2023-01
Completion: 2025-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zanubrutinib	Small molecule	320 mg	—

Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma

Summary

Timeline

Drugs

Indications